logo
This Air Purifier Is the Cheapest on the Market, You Can Stack Discounts to Get It Nearly Free on Amazon

This Air Purifier Is the Cheapest on the Market, You Can Stack Discounts to Get It Nearly Free on Amazon

Gizmodo17 hours ago
Living in a city where air pollution seems unavoidable can feel discouraging, but there's something you can do to protect your health right at home: Investing in an air purifier is a simple way to ensure you breathe cleaner air, especially in your bedroom where you spend nearly a third of your life. You don't have to spend $500 on a Dyson to get quality air cleaning – there are more affordable and practical options too. One of these is the Mooka air purifier (B-D02L), available now on Amazon at a record low price of about $39 after stacking discounts (instant discount + promo code), down from $79.
See at Amazon
The Mooka B-D02L is designed to encompass large rooms, and covers up to 1076 square feet. Since it has a very effective filtration mechanism, it will circulate the air in a 215-square-foot room six times every hour, and perform one full air exchange every hour in larger rooms of up to 1076 square feet. That makes it ideal for a household with pets or children for instance.
The H13 True HEPA filter is the heart of this purifier and it is one of the highest efficiencies in particle capture. It traps pollutants down to 0.3 microns, dust (such as pet hair, dust, pollen, smoke, dander) and odors. The system includes a pre-filter and an activated carbon filter that will work together to catch bigger particles and eradicate stinky odors.
What's extremely important is that it's also very quiet: Its new brushless motor keeps sound at just 20 decibels which is barely audible. That means you can leave it on while doing work or sleeping without being disturbed. And it draws very little power, so you won't notice your electricity bill. If security is your priority, the purifier also features a child lock to prevent accidental modification by curious kids.
Controls on this air purifier are easy to operate: You can have four timer settings (1, 2, 4, or 8 hours) and adjust fan speed via Sleep, Low, Medium, and High. With these controls, you have the power to determine the amount of air you'd like cleaned without wasting energy. There is even a soft night light that will eliminate night stumbling which can be turned off when you want the total blackness of a totally dark room.
If you are looking for a budget-friendly solution to clean the air you and your family breathe, this air purifier is a perfect choice. Don't miss that opportunity on Amazon.
See at Amazon
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Asking Eric: Wife left a gift to niece in her will, but I hesitate to honor it
Asking Eric: Wife left a gift to niece in her will, but I hesitate to honor it

Washington Post

time23 minutes ago

  • Washington Post

Asking Eric: Wife left a gift to niece in her will, but I hesitate to honor it

Dear Eric: When my wife and I updated our wills, she designated a diamond tennis bracelet and diamond stud earrings to her niece (she had no biological children of her own). Later that month my wife was diagnosed with pancreatic cancer to which she would succumb 19 months later. My daughter (my wife's stepdaughter) is a radiation oncologist and became our daily advocate as we navigated the byzantine world of cancer treatment.

Sell HIMS Stock Ahead of Its Earnings?
Sell HIMS Stock Ahead of Its Earnings?

Forbes

timean hour ago

  • Forbes

Sell HIMS Stock Ahead of Its Earnings?

Hims & Hers Health (NYSE:HIMS) is set to announce its earnings on Monday, August 4, 2025. Historically, HIMS stock has reacted unfavorably to earnings announcements. Since 2021, the stock has recorded a negative one-day return in 53% of instances after results. The median one-day decline has amounted to -5.8%, with a maximum one-day decrease of -22.3%. For traders focused on events, grasping these historical trends can be beneficial. While the actual results compared to consensus and expectations will be vital, there are two main strategies to contemplate: Analysts expect HIMS to report earnings of $0.23 per share on revenues of $552 million. This would mark substantial growth compared to the same quarter last year, which recorded earnings of $0.16 per share on revenues of $315 million. A possible positive factor for Hims & Hers' sales growth momentum is the reported underperformance of Novo Nordisk's weight loss medication in the U.S. due to the presence of compounded versions. Regarding fundamentals, HIMS has a market capitalization of $15 billion. Over the past twelve months, the company generated $1.8 billion in revenue and was operationally profitable, reporting $110 million in operating profits and a net income of $164 million. However, if you're looking for upside with less volatility than individual stocks, the Trefis High Quality portfolio offers an alternative — it has outperformed the S&P 500 and achieved returns exceeding 91% since its inception. Additionally, see – Is There More Upside For MSFT Stock? Review earnings reaction history of all stocks HIMS Stock Historical Likelihood of Positive Post-Earnings Return Here are some insights on one-day (1D) post-earnings returns: Additional information regarding the observed 5-Day (5D) and 21-Day (21D) returns post earnings is summarized along with the statistics in the table below. HIMS Stock Correlation Between 1D, 5D, and 21D Historical Returns A comparatively lower-risk strategy (though not effective if the correlation is weak) is to understand the relationship between short-term and medium-term returns post earnings, identify a pair that has the highest correlation, and perform the corresponding trade. For instance, if 1D and 5D exhibit the highest correlation, a trader can take a "long" position for the next 5 days if the 1D post-earnings return is positive. Here is some correlation information based on a 5-year and 3-year (more recent) timeframe. Note that the correlation 1D_5D denotes the relationship between 1D post-earnings returns and subsequent 5D returns. Discover more about the Trefis RV strategy that has outperformed its all-cap stocks benchmark (a blend of the S&P 500, S&P mid-cap, and Russell 2000), delivering strong results for investors. Additionally, if you seek upside with a smoother experience than an individual stock like Hims & Hers Health, consider the High Quality portfolio, which has surpassed the S&P and yielded >91% returns since its inception.

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025

Yahoo

timean hour ago

  • Yahoo

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, July 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, August 13, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's second quarter 2025 financial results. The webcast will be available at the investor relations section of the Company's website at Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join. Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at About Lucid DiagnosticsLucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients. For more information, please visit and for more information about its parent company PAVmed, please visit View original content to download multimedia: SOURCE Lucid Diagnostics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store